9/25/2013

Bioheart, a company that specializes in developing autologous cell treatments for heart damage and severe peripheral vascular disease, secured the rights to use Invitrx Therapeutics' adipose-based stem cell products under a licensing agreement. Preliminary results from an early-stage clinical study could be released soon.

Related Summaries